Incomplete Inhalation of Laninamivir Octanoate in Children with

@inproceedings{Otabe2015IncompleteIO,
  title={Incomplete Inhalation of Laninamivir Octanoate in Children with},
  author={Osamu Otabe and Satoshi Sakaue and Yusuke Tsuma and M. Yamaguchi and Fumihiro Matsui and Masaya Suematsu and Hisato Ito},
  year={2015}
}
Background: Laninamivir octanoate (LO), an inhaled neuraminidase inhibitor, has been used against influenza in Japan. However, children who cannot inhale well might not receive the full dose. We examined the relation between the residual amounts of LO in the device after its use and the time to fever resolution in children with influenza. Methods: The subjects of the study were 161 children (4-15 years) who had been diagnosed as having influenza from 2011-2014 and who had demonstrated an… 
Impact of the number of repeated inhalations and patient characteristics on the residual amount of inhaled laninamivir octanoate hydrate dry powder in pediatric patients with influenza
TLDR
A proportion of patients with low peak inspiratory flow were unable to inhale the active ingredient adequately when laninamivir dry powder inhaler was administered as two successive inhalations, as recommended in the instruction manual.

References

SHOWING 1-10 OF 13 REFERENCES
Effect of a Single Inhalation of Laninamivir Octanoate in Children With Influenza
TLDR
The data suggest that the efficiency and safety of LO are the same as those of ZN in pediatric patients with influenza but that LO may be more convenient than ZN because it requires only a single inhalation, however, younger patients may not inhale LO efficiently.
Survey of the proper use of instructions and compliance for laninamivir octanoate dry powder inhalation in community pharmacies for treatment of influenza
TLDR
It is revealed that many cases of inhalation failure of LO anti-influenza therapy occur below the age of 9 year, and a 4- years-old patient was the youngest to fail LO therapy whereas a 5-years-old patients was the oldest to succeeded with the therapy.
Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus Infection
TLDR
Laninamivir octanoate was an effective and well-tolerated treatment for children with oseltamiviral-resistant influenza A (H1N1) virus infection and its ease of administration is noteworthy, because a single inhalation is required during the course of illness.
Widespread use of neuraminidase inhibitors in Japan
  • N. Sugaya
  • Medicine
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  • 2011
Almost all patients with an influenza-like illness in Japan are now tested with rapid diagnostic tests, and when positive, they are treated with a neuraminidase inhibitor (NAI). Japan may have had
Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
  • Naoki Kawai, H. Ikematsu, +9 authors S. Kashiwagi
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2009
TLDR
The effectiveness of oseltamivir, but not that of zanamivIR, decreased significantly for H1N1 virus infection during the 2008-2009 season.
Incomplete Inhalation of Laninamivir Octanoate in Children with Influenza
  • 2015
Investigation of inspiratory flow rate and post-administration residual volume of laninamivir
  • Gairai Syounika
  • 2013
Administration setting and status of inhalation of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance
  • Japanese Journal of Chemotherapy
  • 2012
Inavir dry powder inhaler
  • Pharmacia
  • 2012
...
1
2
...